Contact: research.oncologie@uza.be
* Studie on hold
Research Team
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| BT5528-100* | HNSCC | >SOC | Bicyclic peptide (EphA2 + MMAE) |
| 20210023 | MTAP loss (Sq. NSCLC, Esophageal, Gastric) | >SOC | MTAP Expression central; oral AMG193 (PRMT5 inhibitor) |
| ORIGAMI-1* | CRC (wt) | 2L | Anti-EGFR+MET; chemo + amivantamab |
| DO2.22.01* | MET | >SOC | MET mutation / MET ampl (>10GCN); DO-2 oral |
| BI1456-0001 | All solid | >SOC | BI 1831169 oncolytical virus VSV-GP intratumoral |
| GO43860 | NSCLC (CPI naive) | Several | RO7502175 Anti-CCR8 Ab + Atezolizumab |
| PYX-201-101 | Several | Several | PYX-201: ADC (anti-EDB+fibronectin+auristatin); HNSCC/HR+ HER2-negative BC/Chordoma/Cervical/Endometrial/TNBC/Ovarian/Rare H&N |
| Bayer 21820 | GC/GEJ/Melanoma/NSCLC | >SOC | BAY3375968: Anti-CCR8 Ab +/- pembro |
| SC201 (VICTORIA-01) | All solid, without liver m+ | >SOC | SOT201: Fusion protein, PD-1 targeted IL-15 agonist |
| U31402-277 (HERTHENA-PanTumor01) | Several | Several | U3-1402: Patritumab Deruxtecan (HER3-DXd), IV, Q3W Cervical/Bladder/Endometrial/Pancreas |
| BI1438-0007 (DAREON-7) | NEC | 1L | BI764532 + etoposide + platinum in DLL3+ |
| CDR404-001 | HLA+MAGE-A4 | >SOC | CDR404: MHC specific T-cell engager; NSCLC/HNSCC/Uro/TNBC/Syn. sarcoma/Sq. cervical/Liposarcoma/Endom./GC/GEJ/EC/Ovarian |
| 20230223 | MTAP loss (PDAC) | 1L | MTAP expression central; Oral AMG193 (PRMT5 inhibitor) + gemcitabine/nab-paclitaxel or FOLFIRINOX |
| JK06.1.01 | Several | >SOC | JK06: ADC (anti-5T4 + MMAE); Breast/Prostate/NSCLC |
| BI1479-0012 (Beamion BCGC-1) | mBC, mGEAC HER2 amplification | >1L | BI1810631: HER2 inhibitor; In combination with T-DXd or T-DM1 (cohort-dependent) |
| BI1479-0009 (Beamion PANTUMOR-1) | Several | >SOC | Monotherapy BI1810631: HER2 inhibitor; HER2 amplification (i.e., 6 copies): Cervical/Uterine/Agnostic or HER2 mutated: urothelial/breast/GEAC/Agnostic |
| INCB161734-101 | KRASG12D (PDAC and CRC) | >SOC | INCB161734 (inhibitor of KRASG12D) monotherapy or in combination with cetuximab |
| ALKOVE-1 | solid tumors, ALK+ | 2L | Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 (phase 2) |